MDXG 10.20 Mimedx Group Inc $MDXG Hit a 52 week high of 10.53 Closing the day 11/03/14 at 10.20 +0.02 +0.20% With a day low of 10.11 and a total volume of 1,120,078.
MDXG Recent Posts: http://investorshangout.com/Mimedx-Group-Inc-MDXG-64149/
MDXG Mimedx Group Inc Recent Headline News
MiMedx Achieves Record Revenue And Records First Operating Profit
PR Newswire - Thu Oct 30, 6:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its results for the third quarter ended September 30, 2014.
MDXG: 10.20 (+0.02)
Despite the Downtrend, This Strong Buy Stock is Outperforming - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Thu Oct 23, 1:23PM CDT
This top ranked stock has been a winner as of late, and given strong momentum, it could continue to soar.
MDXG: 10.20 (+0.02)
MiMedx Provides Update On Outstanding Patent Litigation
PR Newswire - Tue Oct 21, 11:07AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, issued an update on its outstanding patent litigations.
MDXG: 10.20 (+0.02)
Can MiMedx Group (MDXG) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 7:44AM CDT
MiMedx Group could be a great candidate for another beat after a solid performance in the last two quarters
MDXG: 10.20 (+0.02)
Surging Earnings Estimates Signal Good News for MiMedx Group (MDXG) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 7:46AM CDT
MiMedx Group has decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
MDXG: 10.20 (+0.02)
MiMedx (MDXG) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:41AM CDT
MiMedx (MDXG) Shares March Higher, Can It Continue?
MDXG: 10.20 (+0.02)
MiMedx At Fall 2014 SAWC: Studies And Key Opinion Leaders Present Clinical Evidence Of EpiFix Healing Results On Chronic And Acute Wounds
PR Newswire - Thu Oct 16, 9:07AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG) EpiFix® dehydrated human amnion/chorion membrane (dHACM) allografts have been shown to be clinically effective in the treatment of hard-to-heal wounds such as diabetic foot ulcers (DFUs), pressure ulcers (PrUs), and extensive life threatening wounds. Data and case studies demonstrating the clinical efficacy of EpiFix® are being presented at the Fall Symposium on Advanced Wound Care, the leading national wound healing conference, beginning today, October 16, 2014, and concluding on October 18, 2014.
MDXG: 10.20 (+0.02)
MiMedx Group (MDXG) Worth Watching: Stock Rises 9.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:39AM CDT
MiMedx Group, Inc. (MDXG) was a big mover last session, as its shares rose nearly 10% on the day.
MACK: 9.14 (-0.03), MYGN: 39.48 (-0.01), HALO: 9.50 (-0.12), MDXG: 10.20 (+0.02)
MiMedx Third Quarter Revenue Of $33.5 Million Exceeds Upper End Of Guidance
PR Newswire - Mon Oct 13, 6:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today record revenue results for the third quarter of 2014 and issued updated guidance.
MDXG: 10.20 (+0.02)
MiMedx Announces Release Date for 2014 Third Quarter Results
PR Newswire - Mon Oct 06, 3:29PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that its results for the third quarter, ended September 30, 2014, will be released before the opening of the market on Thursday, October 30, 2014. MiMedx will host a live broadcast of its third quarter conference call on Thursday, October 30, 2014, at 10:30am EDT. A listen-only simulcast of the MiMedx conference call will be available online at the Company's website, www.mimedx.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company's website at www.mimedx.com.
MDXG: 10.20 (+0.02)
MiMedx to Present at the Stem Cell Meeting on the Mesa
PR Newswire - Tue Sep 30, 3:08PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that Dr. Tom Koob, Ph.D., Chief Scientific Officer, will present at the Stem Cell Meeting on the Mesa. Dr. Koob will present on Tuesday, October 7, 2014, at 5:00PM Pacific Daylight Time.
MDXG: 10.20 (+0.02)
MiMedx Signs Distribution Agreement With Zimmer
PR Newswire - Thu Sep 18, 8:29AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has entered into a distribution agreement with Zimmer, Inc. Through the agreement, MiMedx will provide its dehydrated human amnion/chorion membrane ("dHACM"
allograft products to Zimmer to be marketed non- exclusively on a private label basis.
MDXG: 10.20 (+0.02)
MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal
PR Newswire - Wed Sep 17, 12:40PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today the publication of another peer-reviewed clinical study.
MDXG: 10.20 (+0.02)
MiMedx To Webcast Its Analyst Day On October 14th
PR Newswire - Mon Sep 08, 3:49PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will be hosting and webcasting its Analyst Day on Tuesday, October 14, 2014, in New York, New York. Parker H. "Pete" Petit, Chairman and CEO; William C. Taylor, President and COO; Michael J. Senken, Chief Financial Officer; and other members of MiMedx senior management will present and be on hand to participate in questions and answers.
MDXG: 10.20 (+0.02)
Fifth MiMedx Scientific Study Published In Peer-Reviewed Journal
PR Newswire - Wed Sep 03, 8:34AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today the publication of another peer-reviewed scientific study in the scientific literature.
MDXG: 10.20 (+0.02)
MiMedx To Present At 34th Annual Canaccord|Genuity Growth Conference
PR Newswire - Mon Aug 04, 12:33PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 34th Annual Canaccord|Genuity Growth Conference in Boston, Massachusetts. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Thursday, August 14th at 2:00 p.m. EDT, at the InterContinental Boston. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MDXG: 10.20 (+0.02)
/C O R R E C T I O N -- MiMedx Group, Inc./
PR Newswire - Mon Jul 28, 10:00PM CDT
In the news release, MiMedx Announces Record Second Quarter Results, issued 28-Jul-2014 by MiMedx Group, Inc. over PR Newswire, we are advised by the company that under the "Highlights include section," the fourth bulletpoint should read "Company issues third quarter revenue guidance of $30-$32 million with Operating Profit" rather than "Company issues third quarter revenue guidance of $30-$31 million with Operating Profit" as originally issued inadvertently. Additional stylistic changes have been made as well. The complete, corrected release follows:
MDXG: 10.20 (+0.02)
MiMedx Announces Record Second Quarter Results
PR Newswire - Mon Jul 28, 3:11PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the quarter ended June 30, 2014.
MDXG: 10.20 (+0.02)
MiMedx Files Its Initial Investigational New Drug Application
PR Newswire - Wed Jul 23, 6:59AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today it has filed its initial Investigational New Drug ("IND" application with the Food and Drug Administration ("FDA" .
MDXG: 10.20 (+0.02)
Restrospective Analysis Finds MiMedx EpiFix® As Most Effective In Rapid Resolution Of Diabetic Foot Ulcers When Compared With Two Other Skin Substitutes
PR Newswire - Tue Jul 22, 3:51PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced for investors today that a peer-reviewed study, "An Evaluation of Healing Metrics Associated with Commonly Used Advanced Wound Care products for the Treatment of Chronic Diabetic Foot Ulcers," was electronically published in the July 2014 edition of Managed Care.
MDXG: 10.20 (+0.02)
MDXG Recent Posts: http://investorshangout.com/Mimedx-Group-Inc-MDXG-64149/
MDXG Mimedx Group Inc Recent Headline News
MiMedx Achieves Record Revenue And Records First Operating Profit
PR Newswire - Thu Oct 30, 6:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its results for the third quarter ended September 30, 2014.
MDXG: 10.20 (+0.02)
Despite the Downtrend, This Strong Buy Stock is Outperforming - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Thu Oct 23, 1:23PM CDT
This top ranked stock has been a winner as of late, and given strong momentum, it could continue to soar.
MDXG: 10.20 (+0.02)
MiMedx Provides Update On Outstanding Patent Litigation
PR Newswire - Tue Oct 21, 11:07AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, issued an update on its outstanding patent litigations.
MDXG: 10.20 (+0.02)
Can MiMedx Group (MDXG) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 7:44AM CDT
MiMedx Group could be a great candidate for another beat after a solid performance in the last two quarters
MDXG: 10.20 (+0.02)
Surging Earnings Estimates Signal Good News for MiMedx Group (MDXG) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 7:46AM CDT
MiMedx Group has decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
MDXG: 10.20 (+0.02)
MiMedx (MDXG) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:41AM CDT
MiMedx (MDXG) Shares March Higher, Can It Continue?
MDXG: 10.20 (+0.02)
MiMedx At Fall 2014 SAWC: Studies And Key Opinion Leaders Present Clinical Evidence Of EpiFix Healing Results On Chronic And Acute Wounds
PR Newswire - Thu Oct 16, 9:07AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG) EpiFix® dehydrated human amnion/chorion membrane (dHACM) allografts have been shown to be clinically effective in the treatment of hard-to-heal wounds such as diabetic foot ulcers (DFUs), pressure ulcers (PrUs), and extensive life threatening wounds. Data and case studies demonstrating the clinical efficacy of EpiFix® are being presented at the Fall Symposium on Advanced Wound Care, the leading national wound healing conference, beginning today, October 16, 2014, and concluding on October 18, 2014.
MDXG: 10.20 (+0.02)
MiMedx Group (MDXG) Worth Watching: Stock Rises 9.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:39AM CDT
MiMedx Group, Inc. (MDXG) was a big mover last session, as its shares rose nearly 10% on the day.
MACK: 9.14 (-0.03), MYGN: 39.48 (-0.01), HALO: 9.50 (-0.12), MDXG: 10.20 (+0.02)
MiMedx Third Quarter Revenue Of $33.5 Million Exceeds Upper End Of Guidance
PR Newswire - Mon Oct 13, 6:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today record revenue results for the third quarter of 2014 and issued updated guidance.
MDXG: 10.20 (+0.02)
MiMedx Announces Release Date for 2014 Third Quarter Results
PR Newswire - Mon Oct 06, 3:29PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that its results for the third quarter, ended September 30, 2014, will be released before the opening of the market on Thursday, October 30, 2014. MiMedx will host a live broadcast of its third quarter conference call on Thursday, October 30, 2014, at 10:30am EDT. A listen-only simulcast of the MiMedx conference call will be available online at the Company's website, www.mimedx.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company's website at www.mimedx.com.
MDXG: 10.20 (+0.02)
MiMedx to Present at the Stem Cell Meeting on the Mesa
PR Newswire - Tue Sep 30, 3:08PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that Dr. Tom Koob, Ph.D., Chief Scientific Officer, will present at the Stem Cell Meeting on the Mesa. Dr. Koob will present on Tuesday, October 7, 2014, at 5:00PM Pacific Daylight Time.
MDXG: 10.20 (+0.02)
MiMedx Signs Distribution Agreement With Zimmer
PR Newswire - Thu Sep 18, 8:29AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has entered into a distribution agreement with Zimmer, Inc. Through the agreement, MiMedx will provide its dehydrated human amnion/chorion membrane ("dHACM"
allograft products to Zimmer to be marketed non- exclusively on a private label basis. MDXG: 10.20 (+0.02)
MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal
PR Newswire - Wed Sep 17, 12:40PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today the publication of another peer-reviewed clinical study.
MDXG: 10.20 (+0.02)
MiMedx To Webcast Its Analyst Day On October 14th
PR Newswire - Mon Sep 08, 3:49PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will be hosting and webcasting its Analyst Day on Tuesday, October 14, 2014, in New York, New York. Parker H. "Pete" Petit, Chairman and CEO; William C. Taylor, President and COO; Michael J. Senken, Chief Financial Officer; and other members of MiMedx senior management will present and be on hand to participate in questions and answers.
MDXG: 10.20 (+0.02)
Fifth MiMedx Scientific Study Published In Peer-Reviewed Journal
PR Newswire - Wed Sep 03, 8:34AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today the publication of another peer-reviewed scientific study in the scientific literature.
MDXG: 10.20 (+0.02)
MiMedx To Present At 34th Annual Canaccord|Genuity Growth Conference
PR Newswire - Mon Aug 04, 12:33PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 34th Annual Canaccord|Genuity Growth Conference in Boston, Massachusetts. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Thursday, August 14th at 2:00 p.m. EDT, at the InterContinental Boston. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MDXG: 10.20 (+0.02)
/C O R R E C T I O N -- MiMedx Group, Inc./
PR Newswire - Mon Jul 28, 10:00PM CDT
In the news release, MiMedx Announces Record Second Quarter Results, issued 28-Jul-2014 by MiMedx Group, Inc. over PR Newswire, we are advised by the company that under the "Highlights include section," the fourth bulletpoint should read "Company issues third quarter revenue guidance of $30-$32 million with Operating Profit" rather than "Company issues third quarter revenue guidance of $30-$31 million with Operating Profit" as originally issued inadvertently. Additional stylistic changes have been made as well. The complete, corrected release follows:
MDXG: 10.20 (+0.02)
MiMedx Announces Record Second Quarter Results
PR Newswire - Mon Jul 28, 3:11PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the quarter ended June 30, 2014.
MDXG: 10.20 (+0.02)
MiMedx Files Its Initial Investigational New Drug Application
PR Newswire - Wed Jul 23, 6:59AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today it has filed its initial Investigational New Drug ("IND"
application with the Food and Drug Administration ("FDA" . MDXG: 10.20 (+0.02)
Restrospective Analysis Finds MiMedx EpiFix® As Most Effective In Rapid Resolution Of Diabetic Foot Ulcers When Compared With Two Other Skin Substitutes
PR Newswire - Tue Jul 22, 3:51PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced for investors today that a peer-reviewed study, "An Evaluation of Healing Metrics Associated with Commonly Used Advanced Wound Care products for the Treatment of Chronic Diabetic Foot Ulcers," was electronically published in the July 2014 edition of Managed Care.
MDXG: 10.20 (+0.02)
